NCT01767194 2022-10-24Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed NeuroblastomaNational Cancer Institute (NCI)Phase 2 Completed73 enrolled 12 charts